- Trial phase
- Approved
- Time to market
- Already approved and marketed since May 2017 (RA); latest label expansion (pJIA) approved June 2024
- Why 3/10
- Kevzara is already approved and marketed (RA since 2017, PMR since 2023, pJIA since 2024) with no pending PDUFA, pivotal readout, or regulatory decision in the next ~12 months. As a commercial-stage drug within a large, diversified biotech ($14.3B revenue in 2025), there is no hard binary catalyst ahead for this product alone.
Kevzara is a steadily growing but non-blockbuster commercial drug for Regeneron. It contributes to Sanofi collaboration revenue but is dwarfed by Dupixent (~$17.8B global sales vs Kevzara's ~$600M). Investors should focus on Regeneron's bigger catalysts: the August 2026 PDUFA for garetosmab (FOP) and Dupixent label expansions, not Kevzara.
Price Chart
Executive Summary
Kevzara (sarilumab) is an injectable IL-6 receptor blocker jointly developed and commercialized by Regeneron (REGN) and Sanofi (SNY). It was first FDA-approved in 2017 for rheumatoid arthritis, and has since expanded to polymyalgia rheumatica (2023) and polyarticular juvenile idiopathic arthritis (2024). Global sales reached roughly $600M in 2025, growing ~27% YoY, but the drug has fallen short of early $1B+ blockbuster expectations and faces entrenched competition from Roche's Actemra (tocilizumab). For Regeneron investors, Kevzara is a modest contributor, it is bundled into Sanofi collaboration revenues ($7.33B in 2025) alongside the far larger Dupixent ($17.8B global sales). There are no upcoming binary catalysts for Kevzara, making it a steady commercial product rather than a share-price driver.
How It Works
Kevzara is a lab-made antibody that blocks the interleukin-6 (IL-6) receptor. IL-6 is a protein that drives inflammation in the body. By sticking to and blocking the IL-6 receptor, Kevzara reduces inflammation, joint pain, and swelling in autoimmune conditions like rheumatoid arthritis.
Trial Status
Kevzara is FDA-approved across three indications: moderate-to-severe rheumatoid arthritis (RA, approved May 2017), polymyalgia rheumatica (PMR, approved Feb 2023 as the first and only biologic for this condition), and active polyarticular juvenile idiopathic arthritis (pJIA, approved June 2024). It is also approved in the EU. Earlier Phase 3 trials in COVID-19 failed to meet primary endpoints.
The Two-Sided Case
Upcoming Catalysts
- No specific upcoming catalysts for Kevzara identified. The drug is fully approved with its latest label expansion (pJIA) completed in June 2024.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report